AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that can co-operate with E17K

Oncogene

Volumn 29, Issue 1, 2010, Pages 150-155

  Askham, J M ^a   Platt, F ^a   Chambers, P A ^a   Snowden, H ^a   Taylor, C F ^a   Knowles, M A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

AKT1; Bladder cancer; Mutation

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE AKT1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM REPEAT; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; GENE FREQUENCY; HUMANS; MICE; MUTATION, MISSENSE; NIH 3T3 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SERINE; THREONINE; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 73849134249     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.315     Document Type: Article

References (27)

1. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. (1999). Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 80: 904-908.
2. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D et al. (1998). Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17: 313-325.
3. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M et al. (2008). AKT1(E17K) in human solid tumours. Oncogene 27: 5648-5650.
4. Bozulic L, Surucu B, Hynx D, Hemmings BA. (2008). PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30: 203-213.
5. Brugge J, Hung MC, Mills GB. (2007). A new mutational AKTivation in the PI3K pathway. Cancer Cell 12: 104-107.
6. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG et al. (1998). Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16: 3215-3218.
7. Calleja V, Alcor D, Laguerre M, Park J, Vojnovic B, Hemmings BA et al. (2007). Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 5: e95.
8. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. (1997). Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 14: 3059-3066.
9. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
10. Dong B, Valencia CA, Liu R. (2007). Ca(2+)/calmodulin directly interacts with the pleckstrin homology domain of AKT1. J Biol Chem 282: 25131-25140.
11. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
12. Kim MS, Jeong EG, Yoo NJ, Lee SH. (2008). Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-1535.
13. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. (2003). Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 63: 7652-7656.
14. Kumar R, Hung MC. (2005). Signaling intricacies take center stage in cancer cells. Cancer Res 65: 2511-2515.
15. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. (2000). The proto-oncogene TCL1 is an Akt kinase coactivator. Mol Cell 6: 395-407.
16. Landgraf KE, Pilling C, Falke JJ. (2008). Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47: 12260-12269.
17. Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A et al. (2006). PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401-7404.
18. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S et al. (2008). Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7: 665-669.
19. Manning BD, Cantley LC. (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
20. Milburn CC, Deak M, Kelly SM, Price NC, Alessi DR, Van Aalten DM. (2003). Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J 375: 531-538.
21. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles M.A. (2009). Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Can Res (in press
22. Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. (2008). Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet 17: 2006-2017.
23. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
24. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al. (2001). AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431-437.
25. Thomas CC, Deak M, Alessi DR, van Aalten DM. (2002). High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 12: 1256-1262.
26. Tokuda E, Fujita N, Oh-hara T, Sato S, Kurata A, Katayama R et al. (2007). Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo. Cancer Res 67: 9666-9676.
27. Wang DS, Rieger-Christ K, Latini JM, Moinzadeh A, Stoffel J, Pezza JA et al. (2000). Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 88: 620-625.